The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H)
Abstract
BACKGROUND: Profound T-cell depletion before allotransplantation with gradual posttransplant T-cell repopulation induces a state of donor-specific immune hyporesponsiveness or tolerance in some animal models. Alemtuzumab (Campath-1H, Millennium Pharmaceuticals, Cambridge, MA) is a humanized CD52-specific monoclonal antibody that produces profound T-cell depletion in humans and reduces the need for maintenance immunosuppression after renal transplantation. We therefore performed a study to determine if pretransplant T-cell depletion with alemtuzumab would induce tolerance in human renal allografts and to evaluate the nature of the alloimmune response in the setting of T-cell depletion. METHODS: Seven nonsensitized recipients of living-donor kidneys were treated perioperatively with alemtuzumab and followed postoperatively without maintenance immunosuppression. Patients were evaluated clinically by peripheral flow cytometry, protocol biopsies evaluated immunohistochemically, and real-time polymerase chain reaction-based transcriptional analysis. RESULTS: Lymphocyte depletion was profound in the periphery and secondary lymphoid tissues. All patients developed reversible rejection episodes within the first month that were characterized by predominantly monocytic (not lymphocytic) infiltrates with only rare T cells in the peripheral blood or allograft. These episodes were responsive to treatment with steroids or sirolimus or both. After therapy, patients remained rejection-free on reduced immunosuppression, generally monotherapy sirolimus, despite the recovery of lymphocytes to normal levels. CONCLUSIONS: T-cell depletion alone does not induce tolerance in humans. These data underscore a prominent role for early responding monocytes in human allograft rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heid, C. A., Stevens, J., Livak, K. J., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,174
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
The Banff 97 working classification of renal allograft pathology
Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M., Castro, M. C., Cavallo, T., Croker, B. P., Demetris, A. J., Drachenberg, C. B., Fogo, A. B., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00299.x · Cited by 3,033
A novel method for real time quantitative RT-PCR.
Gibson, U. E., Heid, C. A., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.995 · Cited by 2,075
Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996
Hariharan, S., Johnson, C. P., Bresnahan, B. A., Taranto, S. E., McIntosh, M. J., & Stablein, D. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003023420901 · Cited by 1,835
High Survival Rates of Kidney Transplants from Spousal and Living Unrelated Donors
Terasaki, P. I., Cecka, J. M., Gjertson, D. W., & Takemoto, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508103330601 · Cited by 1,213
Visualizing the generation of memory CD4 T cells in the whole body
Reinhardt, R. L., Khoruts, A., Merica, R., Zell, T., & Jenkins, M. K. (2001) · Nature · doi:10.1038/35065111 · Cited by 1,026 · cited 1×
“Both of these are potentially derived from activated monocytes, although interferon- is also typically associated with memory T cells and NK cells (26, 27).”
BackgroundLi, Y., Li, X. C., Zheng, X. X., Wells, A. D., Turka, L. A., & Strom, T. B. (1999) · Nature Medicine · doi:10.1038/15256 · Cited by 745
Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance
Wells, A. D., Li, X. C., Li, Y., Walsh, M. C., Zheng, X. X., Wu, Z., Nuñez, G., Tang, A., Sayegh, M., Hancock, W. W., et al. (1999) · Nature Medicine · doi:10.1038/15260 · Cited by 596
Acute graft-versus-host disease does not require alloantigen expression on host epithelium
Teshima, T., Ordemann, R., Reddy, P., Gagin, S., Liu, C., Cooke, K. R., & Ferrara, J. L. M. (2002) · Nature Medicine · doi:10.1038/nm0602-575 · Cited by 521
Cited by
Pearl, J. P., Parris, J., Hale, D. A., Hoffmann, S. C., Bernstein, W. B., McCoy, K. L., Swanson, S. J., Mannon, R. B., Roederer, M., & Kirk, A. D. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00759.x · Cited by 467
Self-citationTransplantation 50 Years Later — Progress, Challenges, and Promises
Sayegh, M. H., & Carpenter, C. B. (2004) · New England Journal of Medicine · doi:10.1056/nejmon043418 · Cited by 425
Organ transplantation—how much of the promise has been realized?
Lechler, R. I., Sykes, M., Thomson, A. W., & Turka, L. A. (2005) · Nature Medicine · doi:10.1038/nm1251 · Cited by 390
Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders
Martin, S. I., Marty, F. M., Fiumara, K., Treon, S. P., Gribben, J. G., & Baden, L. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504811 · Cited by 272
B cells and antibodies in multiple sclerosis pathogenesis and therapy
Krumbholz, M., Derfuss, T., Hohlfeld, R., & Meinl, E. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.203 · Cited by 267
Metadata
- Authors
- Kirk, A. D., Hale, D. A., Mannon, R. B., Kleiner, D. E., Hoffmann, S. C., Kampen, R. L., Cendales, L. K., Tadaki, D. K., Harlan, D. M., & Swanson, S. J.
- Venue
- Transplantation
- Published
- 2003-07
- Volume
- 76
- Issue
- 1
- Pages
- 120-129
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2010606148
- Cited by
- 436
- References
- 20
- FWCI
- 20.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H). https://app.cochat.ai/papers/10.1097/01.tp.0000071362.99021.d9
- The paper
- Kirk, A. D., Hale, D. A., Mannon, R. B., Kleiner, D. E., Hoffmann, S. C., Kampen, R. L., Cendales, L. K., Tadaki, D. K., Harlan, D. M., & Swanson, S. J. (2003). RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H). Transplantation. https://doi.org/10.1097/01.tp.0000071362.99021.d9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.